Measure of atopic dermatitis disease severity using actigraphy.

Area of Science:

• Dermatology
• Sleep Medicine
• Medical Technology

Background:

• Assessing continuous atopic dermatitis (AD) severity is challenging for treatment adherence and outcome analysis.
• Atopic dermatitis significantly impacts patient sleep quality.
• Actigraphy monitoring may provide objective measures of disease burden.

Purpose of the Study:

• To determine if actigraphy devices can continuously measure atopic dermatitis severity.
• To preliminarily assess the effect of a short-course topical corticosteroid on sleep quality.

Main Methods:

• Ten patients with mild to moderate atopic dermatitis used topical fluocinonide 0.1% cream for 5 days.
• Wrist actigraphy monitors recorded sleep data over 14 days.
• Investigator Global Assessment (IGA) and sleep parameters were analyzed.

Main Results:

• Wake after sleep onset (WASO), a sleep disruption marker, correlated with baseline and post-treatment IGA scores (ρ = .75 and ρ = .70).
• IGA scores decreased significantly at days 7 and 14 (p < .05).
• Actigraphy monitors were well-tolerated by participants.

Conclusions:

• Actigraphy effectively demonstrated a positive correlation between atopic dermatitis severity and sleep disturbances.
• Actigraphy is a viable tool for monitoring AD disease burden and its impact on sleep.